All News
RheumNow Podcast – Loretta Lynn Arthritis (3.29.19)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read ArticleCyclosporin and IVIG Effective in Kawasaki's Disease
A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.
Read ArticleNo Rise in Cancer Risk with Actemra
In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.
Read Article2018 Swedish Guidelines for Giant Cell Arteritis Treatment
The Swedish Society of Rheumatology has developed evidence-based guidelines for the management of giant cell arteritis (GCA) with a focus on the appropriate use of corticosteroids and tocilizumab.
Read ArticleNoninfectious Proximal Aortitis Needs Serial Follow-ups
A Cleveland Clinic review of patients undergoing thoracic aortic surgery (1996‐2012) identified 196 patients with histopathology‐proven non‐infectious aortitis.
Read ArticleDoes Methotrexate Work in Giant Cell Arteritis?
There seems to be both hope and uncertainty regarding the use of weekly methotrexate (MTX) in giant cell arteritis (GCA) patients whom need to limit their glucocorticoid use.
Read ArticleIL-6 Blocker Succeeds in Real-World Vasculitis
Tocilizumab (Actemra) was effective for refractory giant cell arteritis (GCA) in real-world practice, although serious infections occurred relatively frequently, Spanish investigators reported.
Read ArticleRheumNow Podcast – A Grand New Year (1.4.19)
Dr. Jack Cush reviews the news and journals for the beginning of 2019. All from RheumNow.com.
Best wishes for a charmed 2019! My advice: 1. Just show up. 2. If you can, then you must do. 3. Live each day as if it twas your 1st day/last day/make or break day. 4. Teach.
RheumNow Podcast – To Needle or Not to Needle (11.30.18)
Dr. Jack Cush updates the news and reports from the past week at RheumNow.com:
Read ArticleFDA Approves Biosimilar Rituximab for NHL, not RA
The U.S. Food and Drug Administration on Wednesday approved Celltrion biosimilar of rituximab called Truxima; previously called CT-P10, now generically labeled as rituximab-abbs. This is the first biosimilar to the Rituxan currently approved to treat non-Hodgkin’s lymphoma. Truxima is not approved for use in rheumatoid arthritis, vasculitis, pemphigus vulgaris or chronic lymphocytic leukemia.
Read ArticleThe RheumNow Podcast – Heartbreak of Methotrexate (11.16.18)
Dr. Jack Cush reviews the news from the past week at RheumNow.com.
Read ArticlePilot Data on Rituximab in Henoch-Schonlein Purpura
Management of Henoch-Schonlein purpura (HSP) can be challenging as supportive care and avoidance of corticosteroids are often insufficient options. A new series of case reports and literature review of steroid refractory HSP suggests that rituximab may be effective in reducing hospital admissions, overall steroid use, and is capable of inducing remission.
Read ArticleIgG4-Related Disease: First Draft Criteria Presented at ACR 2018
As Dr. John Stone, MD, MPH recounted in his presentation regarding the new ACR/EULAR Classification Criteria for IgG4-Related Disease (IgG4-RD), only 15 years prior, IgG4-related disease was an unknown entity in the medical community.
Read ArticleRheumNow ACR Week in Review: ACR Wrap-Up (10.26.18)
This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups. ACR 2018 highlights for me included:
Read ArticleEarly Promise for Steroid-free Approach for Giant Cell Arteritis
A very small study presented at ACR18 looking at tocilizumab monotherapy in patients with a new diagnosis of giant cell arteritis has nevertheless given hope to the tantalising idea that some GCA patients might achieve drug-free remission without steroids, although broader data are requ
Read ArticleACR 2018 - Day 3 Report
Highlights from Tuesday, day 3 of the ACR Annual meeting in Chicago, included:
The PEXIVAS Study – 2x2 Trial of Plasma Exchange and Reduced Steroids in ANCA-Associated Vasculitis (AAV) - Abstract #2788
Read ArticleExcess Mortality in CTD or Systemic Vasculitis Patients
The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.
Read ArticleAn Association between GCA and IBD ?
A population based analysis from Israel suggests that giant cell arteritis (GCA) patients may be at increased risk for inflammatory bowel diseases (IBD) mainly target.
Read ArticleIL-12 and IL-23 Promote Giant Cell Arteritis
It has been postulated that TH1 and TH17 pathways are implicated in the pathogenesis of giant cell arteritis (GCA); this is supported by new research showing that interleukin 12 (IL-12) and interleukin 23 (IL-23) may stimulate inflammatory and proliferative pathways relevant to the path
Read ArticleThe RheumNow Week in Review – No Good Gout (8.10.18)
Dr. Jack Cush reviews the news and latest journal articles from the past week on RheumNow.com. Info on Surgery and Hip Fractures, Gout drugs abandoned, Allopurinol escalation, hydroxychloroquine drug levels, how to treat scleroderma in India and exactly who gets back pain.
Read Article